Who are Bazedoxifene and conjugated estrogens's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): GnRHa with Tamoxifen, DHEA and Acolbifene.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bazedoxifene-and-conjugated-estrogens.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Bazedoxifene and conjugated estrogens — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bazedoxifene and conjugated estrogens (Bazedoxifene and conjugated estrogens) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective Estrogen Receptor Modulator (SERM) combination. Area: Women's Health / Endocrinology.

phase 2 Selective Estrogen Receptor Modulator (SERM) combination Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) Women's Health / Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Bazedoxifene and conjugated estrogens (Bazedoxifene and conjugated estrogens) — Wyeth is now a wholly owned subsidiary of Pfizer. Bazedoxifene is a selective estrogen receptor modulator (SERM) that provides estrogen-like benefits in bone and lipid metabolism while blocking estrogen effects in breast tissue, combined with conjugated estrogens for menopausal symptom relief.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Bazedoxifene and conjugated estrogens TARGET	Bazedoxifene and conjugated estrogens	Wyeth is now a wholly owned subsidiary of Pfizer	phase 2	Selective Estrogen Receptor Modulator (SERM) combination	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
GnRHa with Tamoxifen	GnRHa with Tamoxifen	Asan Medical Center	phase 3	GnRH agonist + selective estrogen receptor modulator (SERM) combination	GnRH receptor (GnRHR) and estrogen receptor (ER)
DHEA and Acolbifene	DHEA and Acolbifene	EndoCeutics Inc.	phase 3	Selective estrogen receptor modulator (SERM) combination	Estrogen receptor alpha and beta

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective Estrogen Receptor Modulator (SERM) combination class)

Wyeth is now a wholly owned subsidiary of Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bazedoxifene and conjugated estrogens — Competitive Intelligence Brief. https://druglandscape.com/ci/bazedoxifene-and-conjugated-estrogens. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab